Next-Generation Anticoagulation Platform: Fast-Acting RNA Origami and DNA Reversal Agent Unveiled

In our latest publication, we introduce a cutting-edge, optimized RNA origami platform designed for anticoagulation therapy. Building on prior work, our platform (HEX01) employs RNA origami as a direct thrombin inhibitor, providing enhanced control over blood clotting. Paired with HEX02, a novel fast-acting single-molecule DNA, this combination offers rapid, on-demand reversal of anticoagulant activity. Our in vivo results show that the RNA origami platform not only provides superior anticoagulation but can also be swiftly reversed, making it an ideal candidate for controlled anticoagulation during surgeries and in emergency situations. This breakthrough has the potential to revolutionize how we approach blood clotting disorders and medical procedures.

Get the publication here: A functional RNA-origami as direct thrombin inhibitor with fast-acting and specific single-molecule reversal agents in vivo model, Mol. Ther., 2024, 32, 2286-2298. doi: 10.1016/j.ymthe.2024.05.002.